In Western blots, less than 25% cross-reactivity with recombinant human (rh) TGF- beta 1.2 and rhTGF-beta 2 is observed, and less than 2% cross-reactivity with recombinant amphibian TGF-beta 5 and recombinant human TGF-beta 1 is observed. This antibody neutralizes the biological activity of TGF-beta 3 but not TGF-beta 1, TGF-beta 2, or TGF-beta 5.
Reconstitute at 0.5 mg/mL in sterile PBS.
Endoxin level is <0.10 EU per 1 µg of the antibody by the LAL method.
Transforming growth factor beta 3 (TGF beta 3) is the third member of the transforming growth factor family of cytokines, which also includes TGF beta 1 and beta 2. These cytokines are secreted in precursor form consisting of a bioactive C-terminal domain attached to an N-terminal domain known as latency associated protein (LAP). Cleavage of LAP results in the mature protein, which functions as a disulfide-linked homodimer. As with all members of the family, TGF beta 3 is highly conserved across species, with mouse and human TGF beta 3 demonstrating 100% sequence homology and cross-species activity.The members of this family can be expressed by most cell types and exert pleiotropic effects, which include the suppression of B- and T-cell effector activity, mediation of tissue healing, and suppression of tumor proliferation. The promotion of CD4+CD25+ T-cell expansion is a newly discovered function of the TGF beta cytokines, and indicates an important role in the protection against autoimmunity.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Protein Aliases: FLJ16571; H-TGF-b-3; LAP; Latency-associated peptide; prepro-transforming growth factor beta-3; tgf beta 3; TGF-beta-3; Transforming growth factor; Transforming growth factor beta-3; Transforming growth factor beta-3 proprotein; transforming growth factor, beta 3
Gene Aliases: ARVD; ARVD1; LDS5; RNHF; TGF-B3; TGF-beta3; Tgfb-3; TGFB3